(NASDAQ: ESPR) Esperion Therapeutics's forecast annual revenue growth rate of 9.58% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Esperion Therapeutics's revenue in 2026 is $403,135,000.On average, 11 Wall Street analysts forecast ESPR's revenue for 2026 to be $106,553,237,087, with the lowest ESPR revenue forecast at $84,991,429,018, and the highest ESPR revenue forecast at $145,675,745,915. On average, 8 Wall Street analysts forecast ESPR's revenue for 2027 to be $103,391,900,053, with the lowest ESPR revenue forecast at $62,918,568,090, and the highest ESPR revenue forecast at $147,013,728,526.
In 2028, ESPR is forecast to generate $144,915,586,888 in revenue, with the lowest revenue forecast at $93,633,101,737 and the highest revenue forecast at $201,619,341,313.